



## Clinical trial results:

### **A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alafenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed**

#### Summary

|                          |                         |
|--------------------------|-------------------------|
| EudraCT number           | 2020-002623-11          |
| Trial protocol           | FR NL GB IE DE AT IT BE |
| Global end of trial date | 17 April 2023           |

#### Results information

|                                |  |
|--------------------------------|--|
| Result version number          | v4 (current)   |
| This version publication date  | 12 July 2024   |
| First version publication date | 28 July 2023   |
| Version creation reason        | <ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Data set corrected based on latest feedback. |

#### Trial information

##### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 213500 |
|-----------------------|--------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT04542070 |
| WHO universal trial number (UTN)   | -           |

Notes:

##### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | ViiV Healthcare  |
| Sponsor organisation address | 980 GreatWest Road, Brentford, Middlesex, United Kingdom, TW8 9GS                |
| Public contact               | ViiV Healthcare, GSK Response Center, 1 8664357343, GSKClinicalSupportHD@gsk.com |
| Scientific contact           | GSK Response Center, ViiV Healthcare, 1 8664357343, GSKClinicalSupportHD@gsk.com |

Notes:

##### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |               |
|--|---------------|
| Analysis stage                                       | Final         |
| Date of interim/final analysis                       | 26 May 2023   |
| Is this the analysis of the primary completion data? | No            |
| Global end of trial reached?                         | Yes           |
| Global end of trial date                             | 17 April 2023 |
| Was the trial ended prematurely?                     | No            |

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate the non-inferior antiviral activity of CAB LA + RPV LA every two months compared to a BIK single tablet regimen administered once daily over 12 months in suppressed HIV-1 infected antiretroviral therapy (ART)-experienced participants.

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

|   |                  |
|---|------------------|
| Actual start date of recruitment                          | 09 November 2020 |
| Long term follow-up planned                               | Yes              |
| Long term follow-up rationale                             | Safety, Efficacy |
| Long term follow-up duration                              | 12 Months        |
| Independent data monitoring committee (IDMC) involvement? | No               |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Belgium: 15        |
| Country: Number of subjects enrolled | Canada: 52         |
| Country: Number of subjects enrolled | France: 33         |
| Country: Number of subjects enrolled | Germany: 39        |
| Country: Number of subjects enrolled | Ireland: 5         |
| Country: Number of subjects enrolled | Japan: 20          |
| Country: Number of subjects enrolled | Australia: 22      |
| Country: Number of subjects enrolled | Netherlands: 9     |
| Country: Number of subjects enrolled | Spain: 78          |
| Country: Number of subjects enrolled | Switzerland: 16    |
| Country: Number of subjects enrolled | United Kingdom: 17 |
| Country: Number of subjects enrolled | United States: 286 |
| Country: Number of subjects enrolled | Austria: 9         |
| Country: Number of subjects enrolled | Italy: 86          |
| Worldwide total number of subjects   | 687                |
| EEA total number of subjects         | 274                |

Notes:

| <b>Subjects enrolled per age group</b>    |     |
|---|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 676 |
| From 65 to 84 years                       | 11  |
| 85 years and over                         | 0   |

## Subject disposition

### Recruitment

Recruitment details:

The study consists in 2 periods: Maintenance Period and Extension Period. Any participants who successfully completed 12 months of CAB+RPV treatment in the Maintenance Phase had the option to enter the Extension Phase and continued to have access to CAB + RPV.

### Pre-assignment

Screening details:

687 participants were enrolled in this study, out of which 681 were included in intent-to-treat exposed population (ITT-E). The Modified ITT-E (excluded participants due to eligibility criteria violations and GCP non-compliance) was used to primarily present the participant flow, baseline characteristics and efficacy analysis. Safety analyses were

### Period 1

|                              |                                       |
|------------------------------|---------------------------------------|
| Period 1 title               | Maintenance Period (Day 1 - Month 12) |
| Is this the baseline period? | Yes                                   |
| Allocation method            | Randomised - controlled               |
| Blinding used                | Not blinded                           |

### Arms

|                              |                          |
|------------------------------|--------------------------|
| Are arms mutually exclusive? | Yes                      |
| <b>Arm title</b>             | Oral lead-in phase (OLI) |

Arm description:

Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM), and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections once every 2 months (Q2M) until Month 12 (Maintenance Phase). The participants had the option to continue the regimen in the Extension Phase.

|  |  |
|--|--|
| Arm type                               | Experimental                           |
| Investigational medicinal product name | Cabotegravir (CAB) + Rilpivirine (RPV) |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Injection, Tablet                      |
| Routes of administration               | Intramuscular use, Oral use            |

Dosage and administration details:

Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM) and then once every 2 months (Q2M) until end of Extension Phase.

|                  |                            |
|------------------|----------------------------|
| <b>Arm title</b> | Direct to injections (D2I) |
|------------------|----------------------------|

Arm description:

Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until Month 11. The participants had the option to continue the regimen in the Extension Phase.

|  |  |
|--|--|
| Arm type                               | Experimental                           |
| Investigational medicinal product name | Cabotegravir (CAB) + Rilpivirine (RPV) |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Injection                              |
| Routes of administration               | Intramuscular use                      |

**Dosage and administration details:**

Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until end of Extension Period.

|  |   |
|--|---|
| <b>Arm title</b>   | Biktarvy (BIK)  |
| Arm description:   |   |
| Participants with HIV-1 received BIK tablet orally until month 12. BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF). |   |
| Arm type   | Active comparator   |
| Investigational medicinal product name   | Bictegravir (BIC) + Emtricitabine (FTC) + Tenofovir alafenamide (TAF) |
| Investigational medicinal product code   |   |
| Other name   |   |
| Pharmaceutical forms   | Tablet  |
| Routes of administration   | Oral use  |

**Dosage and administration details:**

Participants with HIV-1 received BIK tablet orally until month 12. BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF) up to Month 12.

| <b>Number of subjects in period 1<sup>[1]</sup></b> | Oral lead-in phase (OLI) | Direct to injections (D2I) | Biktarvy (BIK) |
|---|--------------------------|----------------------------|----------------|
| Started   | 175                      | 279                        | 227            |
| Completed   | 152                      | 255                        | 213            |
| Not completed                                       | 23                       | 24                         | 14             |
| Consent withdrawn by subject                        | 5                        | 8                          | 9              |
| Physician decision                                  | 1                        | -                          | 1              |
| Adverse event, non-fatal                            | 10                       | 3                          | 1              |
| Protocol Deviation                                  | 2                        | 6                          | 1              |
| Protocol-Specified Withdrawal Criterion Met         | 1                        | 1                          | -              |
| Lost to follow-up                                   | 3                        | 4                          | 2              |
| Lack of efficacy                                    | 1                        | 2                          | -              |

**Notes:**

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Worldwide 687 participants were enrolled, whereof 681 participants were actually included in the study.

**Period 2**

|                              |                                |
|------------------------------|--------------------------------|
| Period 2 title               | Maintenance + Extension Period |
| Is this the baseline period? | No                             |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Not blinded                    |

**Arms**

|                              |     |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

|                  |                          |
|------------------|--------------------------|
| <b>Arm title</b> | Oral lead-in phase (OLI) |
|------------------|--------------------------|

Arm description:

Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM), and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections once every 2 months (Q2M) until Month 12 (Maintenance Phase). The participants had the option to continue the regimen in the Extension Phase.

|  |  |
|--|--|
| Arm type                               | Experimental                           |
| Investigational medicinal product name | Cabotegravir (CAB) + Rilpivirine (RPV) |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Injection, Tablet                      |
| Routes of administration               | Intramuscular use, Oral use            |

Dosage and administration details:

Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM) and then once every 2 months (Q2M) until end of Extension Phase.

|                  |                            |
|------------------|----------------------------|
| <b>Arm title</b> | Direct to injections (D2I) |
|------------------|----------------------------|

Arm description:

Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until Month 11. The participants had the option to continue the regimen in the Extension Phase.

|  |  |
|--|--|
| Arm type                               | Experimental                           |
| Investigational medicinal product name | Cabotegravir (CAB) + Rilpivirine (RPV) |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Injection                              |
| Routes of administration               | Intramuscular use                      |

Dosage and administration details:

Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until end of Extension Period.

| <b>Number of subjects in period 2<sup>[2]</sup></b> | Oral lead-in phase (OLI) | Direct to injections (D2I) |
|---|--------------------------|----------------------------|
|   | Started                  | 173                        |
| Completed   | 150                      | 247                        |
| Not completed                                       | 23                       | 27                         |
| Consent withdrawn by subject                        | 4                        | 12                         |
| Physician decision                                  | 1                        | 1                          |
| Adverse event, non-fatal                            | 10                       | 2                          |
| Protocol-Specified Withdrawal Criterion Met         | 1                        | 1                          |
| Lost to follow-up                                   | 3                        | 4                          |
| Lack of efficacy                                    | 2                        | 2                          |

|                    |   |   |
|--------------------|---|---|
| Protocol deviation | 2 | 5 |
|--------------------|---|---|

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: The participants in Oral lead-in phase (OLI) group and Direct to injections (D2I) group received same treatment regimen in both Maintenance and Extension Periods, hence data was summarized by Maintenance Period and by Maintenance+Extension Period. The Biktarvy (BIK) group was followed only in Maintenance Period, since it was dissolved at the start of Extension Phase, when participants transitioned to Switch Q2M Group or commercial available treatments, based on protocol criteria.

**Period 3**

|                              |  |
|------------------------------|--|
| Period 3 title               | Extension Period (Month 13 - Month 27) |
| Is this the baseline period? | No                                     |
| Allocation method            | Randomised - controlled                |
| Blinding used                | Not blinded                            |

**Arms**

|                  |                  |
|------------------|------------------|
| <b>Arm title</b> | Switch Q2M Group |
|------------------|------------------|

Arm description:

Eligible participants with HIV-1 who received BIK tablet orally switched treatment after month 12 (Extension Phase) to CAB LA 600 mg + RPV LA 900 mg regimen, administered once every 2 months.

|  |  |
|--|--|
| Arm type                               | Active comparator                      |
| Investigational medicinal product name | Cabotegravir (CAB) + Rilpivirine (RPV) |
| Investigational medicinal product code |  |
| Other name                             |  |
| Pharmaceutical forms                   | Injection                              |
| Routes of administration               | Intramuscular use                      |

Dosage and administration details:

Participants received 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM) and then once every 2 months (Q2M) until end of Extension Phase.

| <b>Number of subjects in period 3<sup>[3]</sup></b> | Switch Q2M Group |
|---|------------------|
| Started   | 143              |
| Completed   | 130              |
| Not completed                                       | 13               |
| Consent withdrawn by subject                        | 5                |
| Physician decision                                  | 2                |
| Adverse event, non-fatal                            | 4                |
| Lost to follow-up                                   | 1                |
| Lack of efficacy                                    | 1                |

---

Notes:

[3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Extension Period followed the participants from Oral lead-in phase (OLI), Direct to injections (D2I) and the Switch Q2M groups. The data for Oral lead-in phase (OLI) and Direct to injections (D2I) groups was summarized and presented by Maintenance Period and by Maintenance+Extension Period, hence were not added in this period. The data for Switch Q2M group was summarized and presented only for Extension Period, as this group was formed at the start of Extension Period.

## Baseline characteristics

### Reporting groups

|                       |                          |
|-----------------------|--------------------------|
| Reporting group title | Oral lead-in phase (OLI) |
|-----------------------|--------------------------|

Reporting group description:

Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM), and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections once every 2 months (Q2M) until Month 12 (Maintenance Phase). The participants had the option to continue the regimen in the Extension Phase.

|                       |                            |
|-----------------------|----------------------------|
| Reporting group title | Direct to injections (D2I) |
|-----------------------|----------------------------|

Reporting group description:

Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until Month 11. The participants had the option to continue the regimen in the Extension Phase.

|                       |                |
|-----------------------|----------------|
| Reporting group title | Biktarvy (BIK) |
|-----------------------|----------------|

Reporting group description:

Participants with HIV-1 received BIK tablet orally until month 12. BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF).

| Reporting group values                    | Oral lead-in phase (OLI) | Direct to injections (D2I) | Biktarvy (BIK) |
|---|--------------------------|----------------------------|----------------|
| Number of subjects                        | 175                      | 279                        | 227            |
| Age categorical                           |                          |                            |                |
| Units: Subjects                           |                          |                            |                |
| Over (>=) 18 years of age                 | 175                      | 279                        | 227            |
| Sex: Female, Male                         |                          |                            |                |
| Units: Participants                       |                          |                            |                |
| FEMALE                                    | 27                       | 52                         | 41             |
| MALE                                      | 148                      | 227                        | 186            |
| Race/Ethnicity, Customized                |                          |                            |                |
| Units: Subjects                           |                          |                            |                |
| American Indian or Alaska Native          | 10                       | 4                          | 2              |
| Asian - Central/South Asian Heritage      | 0                        | 3                          | 0              |
| Asian - East Asian Heritage               | 1                        | 0                          | 2              |
| Asian - Japanese Heritage                 | 4                        | 10                         | 6              |
| Asian - South East Asian Heritage         | 2                        | 3                          | 3              |
| Black or African American                 | 40                       | 56                         | 49             |
| Native Hawaiian or Other Pacific Islander | 0                        | 0                          | 1              |
| White - Arabic/North African Heritage     | 10                       | 5                          | 10             |
| White - White/Caucasian/European Heritage | 104                      | 194                        | 149            |
| Mixed White Race                          | 0                        | 0                          | 1              |
| Multiple                                  | 4                        | 4                          | 4              |
| Age, Continuous                           |                          |                            |                |
| Units: YEARS                              |                          |                            |                |
| arithmetic mean                           | 38.5                     | 39.0                       | 38.6           |

|                    |         |         |         |
|--------------------|---------|---------|---------|
| standard deviation | ± 11.38 | ± 11.09 | ± 11.41 |
|--------------------|---------|---------|---------|

| <b>Reporting group values</b>             | Total |  |  |
|---|-------|--|--|
| Number of subjects                        | 681   |  |  |
| Age categorical                           |       |  |  |
| Units: Subjects                           |       |  |  |
| Over (>=) 18 years of age                 | 681   |  |  |
| Sex: Female, Male                         |       |  |  |
| Units: Participants                       |       |  |  |
| FEMALE                                    | 120   |  |  |
| MALE                                      | 561   |  |  |
| Race/Ethnicity, Customized                |       |  |  |
| Units: Subjects                           |       |  |  |
| American Indian or Alaska Native          | 16    |  |  |
| Asian - Central/South Asian Heritage      | 3     |  |  |
| Asian - East Asian Heritage               | 3     |  |  |
| Asian - Japanese Heritage                 | 20    |  |  |
| Asian - South East Asian Heritage         | 8     |  |  |
| Black or African American                 | 145   |  |  |
| Native Hawaiian or Other Pacific Islander | 1     |  |  |
| White - Arabic/North African Heritage     | 25    |  |  |
| White - White/Caucasian/European Heritage | 447   |  |  |
| Mixed White Race                          | 1     |  |  |
| Multiple                                  | 12    |  |  |
| Age, Continuous                           |       |  |  |
| Units: YEARS                              |       |  |  |
| arithmetic mean                           |       |  |  |
| standard deviation                        | -     |  |  |

### Subject analysis sets

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every

2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M

| <b>Reporting group values</b>   | Q2M (OLI + D2I) | Q2M (OLI + D2I) | Q2M (OLI + D2I) |
|---|-----------------|-----------------|-----------------|
| Number of subjects  | 454             | 447             | 2               |
| Age categorical<br>Units: Subjects  |                 |                 |                 |
| Over (>=) 18 years of age   | 454             | 447             | 2               |
| Sex: Female, Male<br>Units: Participants  |                 |                 |                 |
| FEMALE<br>MALE  |                 |                 |                 |
| Race/Ethnicity, Customized<br>Units: Subjects   |                 |                 |                 |
| American Indian or Alaska Native<br>Asian - Central/South Asian Heritage<br>Asian - East Asian Heritage<br>Asian - Japanese Heritage<br>Asian - South East Asian Heritage<br>Black or African American<br>Native Hawaiian or Other Pacific Islander<br>White - Arabic/North African Heritage<br>White - White/Caucasian/European Heritage<br>Mixed White Race<br>Multiple |                 |                 |                 |
| Age, Continuous<br>Units: YEARS<br>arithmetic mean<br>standard deviation  | 1.3<br>±        | 1.1<br>±        | ±               |

| <b>Reporting group values</b>  | Q2M (OLI + D2I) | Q2M (OLI + D2I) | Q2M (OLI + D2I) |
|--|-----------------|-----------------|-----------------|
| Number of subjects   | 1               | 449             | 440             |
| Age categorical<br>Units: Subjects   |                 |                 |                 |
| Over (>=) 18 years of age  | 1               | 449             | 440             |
| Sex: Female, Male<br>Units: Participants   |                 |                 |                 |
| FEMALE<br>MALE   |                 |                 |                 |
| Race/Ethnicity, Customized<br>Units: Subjects  |                 |                 |                 |
| American Indian or Alaska Native<br>Asian - Central/South Asian Heritage<br>Asian - East Asian Heritage<br>Asian - Japanese Heritage<br>Asian - South East Asian Heritage<br>Black or African American |                 |                 |                 |

|   |   |   |   |
|---|---|---|---|
| Native Hawaiian or Other Pacific Islander<br>White - Arabic/North African Heritage<br>White - White/Caucasian/European Heritage<br>Mixed White Race<br>Multiple |   |   |   |
| Age, Continuous<br>Units: YEARS<br>arithmetic mean<br>standard deviation  | ± | ± | ± |

| <b>Reporting group values</b>      | Q2M (OLI + D2I) | Q2M (OLI + D2I) | Q2M (OLI + D2I) |
|------------------------------------|-----------------|-----------------|-----------------|
| Number of subjects                 | 448             | 216             | 182             |
| Age categorical<br>Units: Subjects |                 |                 |                 |
| Over (>=) 18 years of age          | 448             | 216             | 182             |

|   |   |   |   |
|---|---|---|---|
| Sex: Female, Male<br>Units: Participants  |   |   |   |
| FEMALE<br>MALE  |   |   |   |
| Race/Ethnicity, Customized<br>Units: Subjects   |   |   |   |
| American Indian or Alaska Native<br>Asian - Central/South Asian Heritage<br>Asian - East Asian Heritage<br>Asian - Japanese Heritage<br>Asian - South East Asian Heritage<br>Black or African American<br>Native Hawaiian or Other Pacific Islander<br>White - Arabic/North African Heritage<br>White - White/Caucasian/European Heritage<br>Mixed White Race<br>Multiple |   |   |   |
| Age, Continuous<br>Units: YEARS<br>arithmetic mean<br>standard deviation  | ± | ± | ± |

| <b>Reporting group values</b>            | Q2M (OLI + D2I) | Q2M (OLI + D2I) | Q2M (OLI + D2I) |
|--|-----------------|-----------------|-----------------|
| Number of subjects                       | 409             | 446             | 426             |
| Age categorical<br>Units: Subjects       |                 |                 |                 |
| Over (>=) 18 years of age                | 409             | 446             | 426             |
| Sex: Female, Male<br>Units: Participants |                 |                 |                 |
| FEMALE<br>MALE                           |                 |                 |                 |

|   |  |  |                   |
|---|--|--|-------------------|
| Race/Ethnicity, Customized<br>Units: Subjects   |  |  |                   |
| American Indian or Alaska Native<br>Asian - Central/South Asian Heritage<br>Asian - East Asian Heritage<br>Asian - Japanese Heritage<br>Asian - South East Asian Heritage<br>Black or African American<br>Native Hawaiian or Other Pacific Islander<br>White - Arabic/North African Heritage<br>White - White/Caucasian/European Heritage<br>Mixed White Race<br>Multiple |  |  |                   |
| Age, Continuous<br>Units: YEARS<br>arithmetic mean<br>standard deviation  |  |  | 26.97<br>± 10.135 |

|                                    |                 |  |  |
|------------------------------------|-----------------|--|--|
| <b>Reporting group values</b>      | Q2M (OLI + D2I) |  |  |
| Number of subjects                 | 427             |  |  |
| Age categorical<br>Units: Subjects |                 |  |  |
| Over (>=) 18 years of age          | 427             |  |  |

|  |  |  |  |
|--|--|--|--|
| Sex: Female, Male<br>Units: Participants |  |  |  |
| FEMALE<br>MALE                           |  |  |  |

|   |  |  |   |
|---|--|--|---|
| Race/Ethnicity, Customized<br>Units: Subjects   |  |  |   |
| American Indian or Alaska Native<br>Asian - Central/South Asian Heritage<br>Asian - East Asian Heritage<br>Asian - Japanese Heritage<br>Asian - South East Asian Heritage<br>Black or African American<br>Native Hawaiian or Other Pacific Islander<br>White - Arabic/North African Heritage<br>White - White/Caucasian/European Heritage<br>Mixed White Race<br>Multiple |  |  |   |
| Age, Continuous<br>Units: YEARS<br>arithmetic mean<br>standard deviation  |  |  | ± |

## End points

### End points reporting groups

|                       |                          |
|-----------------------|--------------------------|
| Reporting group title | Oral lead-in phase (OLI) |
|-----------------------|--------------------------|

Reporting group description:

Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM), and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections once every 2 months (Q2M) until Month 12 (Maintenance Phase). The participants had the option to continue the regimen in the Extension Phase.

|                       |                            |
|-----------------------|----------------------------|
| Reporting group title | Direct to injections (D2I) |
|-----------------------|----------------------------|

Reporting group description:

Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until Month 11. The participants had the option to continue the regimen in the Extension Phase.

|                       |                |
|-----------------------|----------------|
| Reporting group title | Biktarvy (BIK) |
|-----------------------|----------------|

Reporting group description:

Participants with HIV-1 received BIK tablet orally until month 12. BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF).

|                       |                          |
|-----------------------|--------------------------|
| Reporting group title | Oral lead-in phase (OLI) |
|-----------------------|--------------------------|

Reporting group description:

Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM), and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections once every 2 months (Q2M) until Month 12 (Maintenance Phase). The participants had the option to continue the regimen in the Extension Phase.

|                       |                            |
|-----------------------|----------------------------|
| Reporting group title | Direct to injections (D2I) |
|-----------------------|----------------------------|

Reporting group description:

Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until Month 11. The participants had the option to continue the regimen in the Extension Phase.

|                       |                  |
|-----------------------|------------------|
| Reporting group title | Switch Q2M Group |
|-----------------------|------------------|

Reporting group description:

Eligible participants with HIV-1 who received BIK tablet orally switched treatment after month 12 (Extension Phase) to CAB LA 600 mg + RPV LA 900 mg regimen, administered once every 2 months.

|                            |                 |
|----------------------------|-----------------|
| Subject analysis set title | Q2M (OLI + D2I) |
|----------------------------|-----------------|

|                           |                    |
|---------------------------|--------------------|
| Subject analysis set type | Sub-group analysis |
|---------------------------|--------------------|

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                 |
|----------------------------|-----------------|
| Subject analysis set title | Q2M (OLI + D2I) |
|----------------------------|-----------------|

|                           |                    |
|---------------------------|--------------------|
| Subject analysis set type | Sub-group analysis |
|---------------------------|--------------------|

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every

2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M until Month 11.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Q2M (OLI + D2I)    |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants with HIV-1 who started OLI were administered with Cabotegravir and Rilpivirine (CAB + RPV) tablets orally for one month. At the month 1 visit, the last dose of oral 30 mg CAB + 25 mg RPV tablets were given, followed by the first 600 mg CAB LA + 900 mg RPV LA intramuscular injection, and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections every 2 months (Q2M) until Month 12. Participants with HIV-1 who started with D2I, received the first injection of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading dose at Day 1 followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and 3 followed by Q2M

**Primary: Percentage of participants with plasma human immunodeficiency viruses (HIV)-1 ribonucleic acid (RNA) greater than or equal to ( $\geq$ ) 50 copies per milliliter (c/mL) at Month 12/11 - ITT-E Population**

|                 |   |
|-----------------|---|
| End point title | Percentage of participants with plasma human immunodeficiency viruses (HIV)-1 ribonucleic acid (RNA) greater than or equal to ( $\geq$ ) 50 copies per milliliter (c/mL) at Month 12/11 - ITT-E Population <sup>[1]</sup> |
|-----------------|---|

End point description:

Percentage of participants with plasma HIV 1 RNA  $\geq$  50 c/mL at month 12 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At month 12/11

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                  | Biktarvy (BIK)   | Q2M (OLI + D2I)      |  |  |
|-----------------------------------|------------------|----------------------|--|--|
| Subject group type                | Reporting group  | Subject analysis set |  |  |
| Number of subjects analysed       | 227              | 454                  |  |  |
| Units: Percentage of participants |                  |                      |  |  |
| number (confidence interval 95%)  | 0.4 (0.0 to 2.4) | 1.3 (0.5 to 2.9)     |  |  |

**Statistical analyses**

|   |                                   |
|---|-----------------------------------|
| Statistical analysis title              | Statistical Analysis 2            |
| Comparison groups                       | Biktarvy (BIK) v Q2M (OLI + D2I)  |
| Number of subjects included in analysis | 681                               |
| Analysis specification                  | Pre-specified                     |
| Analysis type                           |                                   |
| Parameter estimate                      | Adjusted difference in percentage |
| Point estimate                          | 0.9                               |
| Confidence interval                     |                                   |
| level                                   | 95 %                              |
| sides                                   | 2-sided                           |
| lower limit                             | -0.5                              |
| upper limit                             | 2.2                               |

|   |                                  |
|---|----------------------------------|
| <b>Statistical analysis title</b>       | Statistical Analysis 1           |
| Comparison groups                       | Biktarvy (BIK) v Q2M (OLI + D2I) |
| Number of subjects included in analysis | 681                              |
| Analysis specification                  | Pre-specified                    |
| Analysis type                           |                                  |
| Parameter estimate                      | Difference in percentage         |
| Point estimate                          | 0.9                              |
| Confidence interval                     |                                  |
| level                                   | 95 %                             |
| sides                                   | 2-sided                          |
| lower limit                             | -0.5                             |
| upper limit                             | 2.2                              |

**Primary: Percentage of participants with plasma HIV-1 RNA greater  $\geq$ 50 copies per milliliter (c/mL) at Month 12/11 - mITT-E Population**

|                 |   |
|-----------------|---|
| End point title | Percentage of participants with plasma HIV-1 RNA greater $\geq$ 50 copies per milliliter (c/mL) at Month 12/11 - mITT-E Population <sup>[2]</sup> |
|-----------------|---|

End point description:

Percentage of participants with plasma HIV 1 RNA  $\geq$  50 c/mL at month 12 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At month 12/11

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| <b>End point values</b>           | Biktarvy (BIK)   | Q2M (OLI + D2I)      |  |  |
|-----------------------------------|------------------|----------------------|--|--|
| Subject group type                | Reporting group  | Subject analysis set |  |  |
| Number of subjects analysed       | 223              | 447                  |  |  |
| Units: Percentage of participants |                  |                      |  |  |
| number (confidence interval 95%)  | 0.4 (0.0 to 2.5) | 1.1 (0.4 to 2.6)     |  |  |

**Statistical analyses**

|                                   |                                  |
|-----------------------------------|----------------------------------|
| <b>Statistical analysis title</b> | Statistical Analysis 4           |
| Comparison groups                 | Biktarvy (BIK) v Q2M (OLI + D2I) |

|   |                                   |
|---|-----------------------------------|
| Number of subjects included in analysis | 670                               |
| Analysis specification                  | Pre-specified                     |
| Analysis type                           |                                   |
| Parameter estimate                      | Adjusted difference in percentage |
| Point estimate                          | 0.7                               |
| Confidence interval                     |                                   |
| level                                   | 95 %                              |
| sides                                   | 2-sided                           |
| lower limit                             | -0.7                              |
| upper limit                             | 2                                 |

|   |                                  |
|---|----------------------------------|
| <b>Statistical analysis title</b>       | Statistical Analysis 3           |
| Comparison groups                       | Biktarvy (BIK) v Q2M (OLI + D2I) |
| Number of subjects included in analysis | 670                              |
| Analysis specification                  | Pre-specified                    |
| Analysis type                           |                                  |
| Parameter estimate                      | Difference in percentage         |
| Point estimate                          | 0.7                              |
| Confidence interval                     |                                  |
| level                                   | 95 %                             |
| sides                                   | 2-sided                          |
| lower limit                             | -0.6                             |
| upper limit                             | 2                                |

### **Secondary: Percentage of participants with plasma HIV-1 RNA less than (<)50 c/mL at Month 12/11 - ITT-E Population**

|                 |  |
|-----------------|--|
| End point title | Percentage of participants with plasma HIV-1 RNA less than (<)50 c/mL at Month 12/11 - ITT-E Population <sup>[3]</sup> |
|-----------------|--|

#### End point description:

Percentage of participants with plasma HIV 1 RNA < 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

#### End point timeframe:

At month 12/11

#### Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                  | Biktarvy (BIK)      | Q2M (OLI + D2I)      |  |  |
|-----------------------------------|---------------------|----------------------|--|--|
| Subject group type                | Reporting group     | Subject analysis set |  |  |
| Number of subjects analysed       | 227                 | 454                  |  |  |
| Units: Percentage of participants |                     |                      |  |  |
| number (confidence interval 95%)  | 93.0 (89.6 to 96.3) | 89.4 (86.6 to 92.3)  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants with plasma HIV-1 RNA <50 c/mL at Month 12/11 -mITT-E Population

|                 |  |
|-----------------|--|
| End point title | Percentage of participants with plasma HIV-1 RNA <50 c/mL at Month 12/11 -mITT-E Population <sup>[4]</sup> |
|-----------------|--|

End point description:

Percentage of participants with plasma HIV 1 RNA < 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At month 12/11

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                  | Biktarvy (BIK)      | Q2M (OLI + D2I)      |  |  |
|-----------------------------------|---------------------|----------------------|--|--|
| Subject group type                | Reporting group     | Subject analysis set |  |  |
| Number of subjects analysed       | 223                 | 447                  |  |  |
| Units: Percentage of participants |                     |                      |  |  |
| number (confidence interval 95%)  | 92.8 (89.4 to 96.2) | 90.2 (87.4 to 92.9)  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants with plasma HIV-1 RNA <50 c/mL at Month 6/5 - ITT-E Population

|                 |  |
|-----------------|--|
| End point title | Percentage of participants with plasma HIV-1 RNA <50 c/mL at Month 6/5 - ITT-E Population <sup>[5]</sup> |
|-----------------|--|

---

**End point description:**

Percentage of participants with plasma HIV 1 RNA < 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

**End point timeframe:**

At month 6/5

**Notes:**

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                  | Biktarvy (BIK)      | Q2M (OLI + D2I)      |  |  |
|-----------------------------------|---------------------|----------------------|--|--|
| Subject group type                | Reporting group     | Subject analysis set |  |  |
| Number of subjects analysed       | 227                 | 454                  |  |  |
| Units: Percentage of participants |                     |                      |  |  |
| number (confidence interval 95%)  | 97.8 (95.9 to 99.7) | 92.7 (90.3 to 95.1)  |  |  |

---

**Statistical analyses**

No statistical analyses for this end point

---

**Secondary: Percentage of participants with plasma HIV-1 RNA <50 c/mL at Month 6/5 - mITT-E Population**

---

|                 |   |
|-----------------|---|
| End point title | Percentage of participants with plasma HIV-1 RNA <50 c/mL at Month 6/5 - mITT-E Population <sup>[6]</sup> |
|-----------------|---|

---

**End point description:**

Percentage of participants with plasma HIV 1 RNA < 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

**End point timeframe:**

At month 6/5

**Notes:**

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                  | Biktarvy (BIK)      | Q2M (OLI + D2I)      |  |  |
|-----------------------------------|---------------------|----------------------|--|--|
| Subject group type                | Reporting group     | Subject analysis set |  |  |
| Number of subjects analysed       | 223                 | 447                  |  |  |
| Units: Percentage of participants |                     |                      |  |  |
| number (confidence interval 95%)  | 97.8 (95.8 to 99.7) | 93.5 (91.2 to 95.8)  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with protocol-defined confirmed virologic failure (CVF) through Month 6/5 and 12/11

|                 |   |
|-----------------|---|
| End point title | Number of participants with protocol-defined confirmed virologic failure (CVF) through Month 6/5 and 12/11 <sup>[7]</sup> |
|-----------------|---|

End point description:

Protocol-defined confirmed virologic failure was defined as rebound as indicated by two consecutive plasma HIV-1 RNA levels  $\geq 200$  c/mL (Day 1 values are not applicable) after prior suppression to  $<200$  c/mL. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at Month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. Cumulative number of participants with protocol defined CVF through Month 6/5 and 12/11 has been presented.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to month 12

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values            | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|-----------------------------|-----------------|----------------------|--|--|
| Subject group type          | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed | 223             | 447                  |  |  |
| Units: Participants         |                 |                      |  |  |
| Month 6/5                   | 0               | 1                    |  |  |
| Month 12/11                 | 0               | 2                    |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants with plasma HIV-1 RNA greater than or equal to ( $\geq$ ) 50 c/mL at Month 6/5

|                 |  |
|-----------------|--|
| End point title | Percentage of participants with plasma HIV-1 RNA greater than or equal to ( $\geq$ ) 50 c/mL at Month 6/5 <sup>[8]</sup> |
|-----------------|--|

---

**End point description:**

Percentage of participants with plasma HIV 1 RNA  $\geq$  50 c/mL at month 6 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

**End point timeframe:**

At month 6/5

**Notes:**

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                  | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|-----------------------------------|-----------------|----------------------|--|--|
| Subject group type                | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed       | 223             | 447                  |  |  |
| Units: Percentage of participants |                 |                      |  |  |
| number (confidence interval 95%)  | 0 (0.0 to 1.6)  | 0.4 (0.1 to 1.6)     |  |  |

---

**Statistical analyses**

No statistical analyses for this end point

---

**Secondary: Change from baseline in HIV viral load**

---

|                 |   |
|-----------------|---|
| End point title | Change from baseline in HIV viral load <sup>[9]</sup> |
|-----------------|---|

---

**End point description:**

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value. Logarithm to base 10 values for plasma HIV-1 RNA has been presented. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

**End point timeframe:**

Baseline (Day 1) and up to Month 12

**Notes:**

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                     | Biktarvy (BIK)      | Q2M (OLI + D2I)      |  |  |
|--------------------------------------|---------------------|----------------------|--|--|
| Subject group type                   | Reporting group     | Subject analysis set |  |  |
| Number of subjects analysed          | 223                 | 447                  |  |  |
| Units: log <sub>10</sub> c/mL        |                     |                      |  |  |
| arithmetic mean (standard deviation) |                     |                      |  |  |
| Baseline (Day 1)                     | 1.5947 (± 0.06640)  | 1.5993 (± 0.10559)   |  |  |
| Month 6/5                            | -0.0039 (± 0.06826) | 0.0015 (± 0.13997)   |  |  |
| Month 12/11                          | -0.0041 (± 0.07172) | 0.0029 (± 0.17038)   |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute values of HIV viral load

|                 |   |
|-----------------|---|
| End point title | Absolute values of HIV viral load <sup>[10]</sup> |
|-----------------|---|

End point description:

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log<sub>10</sub>) values for plasma HIV-1 RNA has been presented. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                                     | Biktarvy (BIK)     | Q2M (OLI + D2I)      |  |  |
|--|--------------------|----------------------|--|--|
| Subject group type                                   | Reporting group    | Subject analysis set |  |  |
| Number of subjects analysed                          | 223                | 447                  |  |  |
| Units: log <sub>10</sub> copies per milliliter(c/mL) |                    |                      |  |  |
| arithmetic mean (standard deviation)                 |                    |                      |  |  |
| Baseline (Day 1)                                     | 1.5947 (± 0.06640) | 1.5993 (± 0.10559)   |  |  |
| Month 6/5  | 1.5910 (± 0.01182) | 1.6002 (± 0.09268)   |  |  |
| Month 12/11  | 1.5911 (± 0.01552) | 1.6019 (± 0.13064)   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Absolute values of cluster of differentiation 4 plus (CD4+) cell count

|                 |  |
|-----------------|--|
| End point title | Absolute values of cluster of differentiation 4 plus (CD4+) cell count <sup>[11]</sup> |
|-----------------|--|

End point description:

Blood samples were collected and CD4+ cell count was assessed using flow cytometry. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values  | Biktarvy (BIK)   | Q2M (OLI + D2I)      |  |  |
|---|------------------|----------------------|--|--|
| Subject group type  | Reporting group  | Subject analysis set |  |  |
| Number of subjects analysed                               | 222              | 447                  |  |  |
| Units: cells per cubic millimeter(cells/mm <sup>3</sup> ) |                  |                      |  |  |
| arithmetic mean (standard deviation)                      |                  |                      |  |  |
| Baseline (Day 1)  | 679.4 (± 306.89) | 670.9 (± 282.11)     |  |  |
| Month 6/5   | 673.7 (± 290.46) | 689.1 (± 284.89)     |  |  |
| Month 12/11   | 717.3 (± 317.82) | 711.9 (± 297.13)     |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in CD4+ cell count

|                 |   |
|-----------------|---|
| End point title | Change from Baseline in CD4+ cell count <sup>[12]</sup> |
|-----------------|---|

End point description:

Blood samples were collected and CD4+ cell count was assessed using flow cytometry. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                     | Biktarvy (BIK)   | Q2M (OLI + D2I)      |  |  |
|--------------------------------------|------------------|----------------------|--|--|
| Subject group type                   | Reporting group  | Subject analysis set |  |  |
| Number of subjects analysed          | 223              | 447                  |  |  |
| Units: cells/mm <sup>3</sup>         |                  |                      |  |  |
| arithmetic mean (standard deviation) |                  |                      |  |  |
| Baseline (Day 1)                     | 679.4 (± 306.89) | 670.9 (± 282.11)     |  |  |
| Month 6/5                            | -3.1 (± 197.62)  | 20.4 (± 202.38)      |  |  |
| Month 12/11                          | 32.2 (± 208.29)  | 35.2 (± 219.79)      |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with treatment-emergent phenotypic resistance through Month 6/5

|                 |  |
|-----------------|--|
| End point title | Number of participants with treatment-emergent phenotypic resistance through Month 6/5 |
|-----------------|--|

End point description:

Blood samples were collected to evaluate the phenotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of phenotype, fold changes to CAB, RPV, and BIC, replication capacity of Integrase, protease, and reverse transcriptase enzymes at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. No participants in the BIK arm met CVF.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Month 6/5

| End point values            | Q2M (OLI + D2I)      |  |  |  |
|-----------------------------|----------------------|--|--|--|
| Subject group type          | Subject analysis set |  |  |  |
| Number of subjects analysed | 1                    |  |  |  |
| Units: Participants         |                      |  |  |  |
| NNRTI                       | 1                    |  |  |  |
| IN                          | 1                    |  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with treatment-emergent phenotypic resistance through Month 12/11

|                 |  |
|-----------------|--|
| End point title | Number of participants with treatment-emergent phenotypic resistance through Month 12/11 |
|-----------------|--|

End point description:

Blood samples were collected to evaluate the phenotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of phenotype, fold changes to CAB, RPV, and BIC, replication capacity of Integrase, protease, and reverse transcriptase enzymes at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. No participants in the BIK arm met CVF.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Month 12/11

| End point values            | Q2M (OLI + D2I)      |  |  |  |
|-----------------------------|----------------------|--|--|--|
| Subject group type          | Subject analysis set |  |  |  |
| Number of subjects analysed | 2                    |  |  |  |
| Units: Participants         |                      |  |  |  |
| NNRTI                       | 2                    |  |  |  |
| IN                          | 2                    |  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with treatment-emergent genotypic resistance through Month 12/11

|                 |   |
|-----------------|---|
| End point title | Number of participants with treatment-emergent genotypic resistance through Month 12/11 |
|-----------------|---|

End point description:

Blood samples were collected to evaluate the genotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of resistance mutations and genotypic susceptibility at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. No participants in the BIK arm met CVF.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Month 12/11

|                             |                      |  |  |  |
|-----------------------------|----------------------|--|--|--|
| <b>End point values</b>     | Q2M (OLI + D2I)      |  |  |  |
| Subject group type          | Subject analysis set |  |  |  |
| Number of subjects analysed | 2                    |  |  |  |
| Units: Participants         |                      |  |  |  |
| M230L                       | 1                    |  |  |  |
| Q148R                       | 1                    |  |  |  |
| K101E                       | 1                    |  |  |  |
| G118R                       | 1                    |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with treatment-emergent genotypic resistance through Month 6/5

|                 |   |
|-----------------|---|
| End point title | Number of participants with treatment-emergent genotypic resistance through Month 6/5 |
|-----------------|---|

End point description:

Blood samples were collected to evaluate the genotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of resistance mutations and genotypic susceptibility at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. No participants in the BIK arm met CVF.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Month 6/5

|                             |                      |  |  |  |
|-----------------------------|----------------------|--|--|--|
| <b>End point values</b>     | Q2M (OLI + D2I)      |  |  |  |
| Subject group type          | Subject analysis set |  |  |  |
| Number of subjects analysed | 1                    |  |  |  |
| Units: Participants         |                      |  |  |  |
| M230L                       | 1                    |  |  |  |
| Q148R                       | 1                    |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in bone biomarkers: specific alkaline phosphatase, procollagen type 1 N-Terminal propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin (micrograms per liter (ug/L))

|                 |   |
|-----------------|---|
| End point title | Change from baseline in bone biomarkers: specific alkaline phosphatase, procollagen type 1 N-Terminal propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin (micrograms |
|-----------------|---|

## End point description:

Serum samples were collected to evaluate bone specific biomarkers: specific alkaline phosphatase, procollagen type 1 N-propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

|                                     |
|-------------------------------------|
| Baseline (Day 1) and up to Month 12 |
|-------------------------------------|

## Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                                  | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|---|-----------------|----------------------|--|--|
| Subject group type                                | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed                       | 227             | 449                  |  |  |
| Units: micrograms per liter (ug/L)                |                 |                      |  |  |
| arithmetic mean (standard deviation)              |                 |                      |  |  |
| Serum Bone Specific Alkaline Phosphatase, Day 1   | 12.9 (± 4.60)   | 12.7 (± 4.27)        |  |  |
| Serum Bone Specific Alkaline Phosphatase, M6/5    | 0.2 (± 2.60)    | 0.3 (± 9.89)         |  |  |
| Serum Bone Specific Alkaline Phosphatase, M12/11  | 0.5 (± 3.55)    | 0.1 (± 5.03)         |  |  |
| Serum Osteocalcin, Day 1                          | 20.4 (± 7.48)   | 21.0 (± 7.35)        |  |  |
| Serum Osteocalcin, Month 6/5                      | -0.4 (± 5.11)   | 0.4 (± 5.53)         |  |  |
| Serum Osteocalcin, M12/11                         | -0.6 (± 5.51)   | 0.9 (± 6.11)         |  |  |
| Serum Procollagen 1 N-Terminal Propeptide, Day 1  | 59.2 (± 23.88)  | 59.1 (± 23.06)       |  |  |
| Serum Procollagen 1 N-Terminal Propeptide, M6/5   | 0.1 (± 18.53)   | -1.5 (± 15.70)       |  |  |
| Serum Procollagen 1 N-Terminal Propeptide, M12/11 | 0.6 (± 19.63)   | -0.7 (± 19.73)       |  |  |
| Serum Type I Collagen C-Telopeptides, Day 1       | 0.5 (± 0.25)    | 0.4 (± 0.25)         |  |  |
| Serum Type I Collagen C-Telopeptides, M6/5        | -0.1 (± 0.21)   | -0.1 (± 0.23)        |  |  |
| Serum Type I Collagen C-Telopeptides, M12/11      | 0.0 (± 0.22)    | 0.0 (± 0.25)         |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline in bone biomarkers: serum 25-hydroxyvitamin D (nanomoles per liter (nmol/L))

|                 |  |
|-----------------|--|
| End point title | Change from baseline in bone biomarkers: serum 25- |
|-----------------|--|

## End point description:

Serum samples were collected to evaluate bone specific biomarkers: serum 25-hydroxyvitamin D. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

Baseline (Day 1) and up to Month 12

## Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                     | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|--------------------------------------|-----------------|----------------------|--|--|
| Subject group type                   | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed          | 219             | 440                  |  |  |
| Units: nanomoles per liter (nmol/L)  |                 |                      |  |  |
| arithmetic mean (standard deviation) |                 |                      |  |  |
| Baseline (Day 1)                     | 59.9 (± 33.30)  | 61.0 (± 34.69)       |  |  |
| Month 6/5                            | 6.0 (± 34.16)   | 2.8 (± 29.24)        |  |  |
| Month 12/11                          | -3.1 (± 26.38)  | -2.3 (± 29.00)       |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in renal biomarkers: specific serum beta-2 microglobulin, cystatin c, retinol binding protein, urine beta-2 microglobulin (milligrams per liter [mg/L])

|                 |  |
|-----------------|--|
| End point title | Change from baseline in renal biomarkers: specific serum beta-2 microglobulin, cystatin c, retinol binding protein, urine beta-2 microglobulin (milligrams per liter [mg/L]) <sup>[15]</sup> |
|-----------------|--|

## End point description:

Serum samples were collected to evaluate renal specific biomarkers: specific serum beta-2 microglobulin, cystatin c, retinol binding protein, urine beta-2 microglobulin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                                | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|---|-----------------|----------------------|--|--|
| Subject group type                              | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed                     | 227             | 448                  |  |  |
| Units: milligrams per liter (mg/L)              |                 |                      |  |  |
| arithmetic mean (standard deviation)            |                 |                      |  |  |
| Serum beta-2 microglobulin, Baseline (Day 1)    | 1.8 (± 0.38)    | 1.8 (± 0.40)         |  |  |
| Serum beta-2 microglobulin, Month 6/5           | 0.0 (± 0.28)    | 0.0 (± 0.28)         |  |  |
| Serum beta-2 microglobulin, Month 12/11         | 0.0 (± 0.32)    | 0.0 (± 0.33)         |  |  |
| Serum cystatin C, Baseline (Day 1)              | 0.9 (± 0.14)    | 0.9 (± 0.13)         |  |  |
| Serum cystatin C, Month 6/5                     | 0.0 (± 0.08)    | 0.0 (± 0.08)         |  |  |
| Serum cystatin C, Month 12/11                   | 0.0 (± 0.08)    | 0.0 (± 0.08)         |  |  |
| Serum retinol binding protein, Baseline (Day 1) | 52.2 (± 12.61)  | 51.3 (± 13.01)       |  |  |
| Serum retinol binding protein, Month 6/5        | -0.3 (± 8.75)   | -1.0 (± 9.00)        |  |  |
| Serum retinol binding protein, Month 12/11      | 0.2 (± 9.06)    | -1.2 (± 9.24)        |  |  |
| Urine beta-2 microglobulin, Baseline (Day 1)    | 0.2 (± 0.40)    | 0.2 (± 0.34)         |  |  |
| Urine beta-2 microglobulin, Month 6/5           | 0.1 (± 0.65)    | 0.0 (± 0.40)         |  |  |
| Urine beta-2 microglobulin, Month 12/11         | 0.1 (± 0.52)    | 0.0 (± 0.24)         |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline in renal biomarkers: urine phosphate (millimoles per liter (mmol/L))

|                 |   |
|-----------------|---|
| End point title | Change from baseline in renal biomarkers: urine phosphate (millimoles per liter (mmol/L)) <sup>[16]</sup> |
|-----------------|---|

End point description:

Serum samples were collected to evaluate renal specific biomarkers: urine phosphate. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                     | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|--------------------------------------|-----------------|----------------------|--|--|
| Subject group type                   | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed          | 223             | 449                  |  |  |
| Units: millimoles per liter (mmol/L) |                 |                      |  |  |
| arithmetic mean (standard deviation) |                 |                      |  |  |
| Baseline (Day 1)                     | 18.4 (± 13.10)  | 20.0 (± 14.03)       |  |  |
| Month 6/5                            | 0.4 (± 15.60)   | -1.0 (± 16.29)       |  |  |
| Month 12/11                          | -0.6 (± 15.16)  | 0.1 (± 16.17)        |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline in renal biomarker: urine retinol binding protein 4 (microgram per liter (ug/L))

|                 |   |
|-----------------|---|
| End point title | Change from baseline in renal biomarker: urine retinol binding protein 4 (microgram per liter (ug/L)) <sup>[17]</sup> |
|-----------------|---|

End point description:

Serum samples were collected to evaluate renal specific biomarkers: urine retinol binding protein 4. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                     | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|--------------------------------------|-----------------|----------------------|--|--|
| Subject group type                   | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed          | 222             | 447                  |  |  |
| Units: microgram per liter (ug/L)    |                 |                      |  |  |
| arithmetic mean (standard deviation) |                 |                      |  |  |
| Baseline (Day 1)                     | 100.0 (± 82.00) | 114.2 (± 111.45)     |  |  |
| Month 6/5                            | 5.7 (± 105.08)  | 0.8 (± 139.88)       |  |  |
| Month 12/11                          | -1.2 (± 105.26) | -0.6 (± 123.52)      |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in renal biomarker: urine retinol binding protein/creatinine (milligram per mole (mg/mol))

|                 |   |
|-----------------|---|
| End point title | Change from baseline in renal biomarker: urine retinol binding protein/creatinine (milligram per mole (mg/mol)) <sup>[18]</sup> |
|-----------------|---|

End point description:

Serum samples were collected to evaluate renal specific biomarkers: urine retinol binding protein/creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                     | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|--------------------------------------|-----------------|----------------------|--|--|
| Subject group type                   | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed          | 107             | 216                  |  |  |
| Units: milligram per mole (mg/mol)   |                 |                      |  |  |
| arithmetic mean (standard deviation) |                 |                      |  |  |
| Baseline (Day 1)                     | 8.0 (± 5.75)    | 8.6 (± 6.32)         |  |  |
| Month 6/5                            | -0.8 (± 7.23)   | 0.8 (± 6.00)         |  |  |
| Month 12/11                          | 0.0 (± 4.15)    | -0.5 (± 6.41)        |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in renal biomarker: urine beta-2 microglobulin/creatinine (grams per mole (g/mol))

|                 |   |
|-----------------|---|
| End point title | Change from baseline in renal biomarker: urine beta-2 microglobulin/creatinine (grams per mole (g/mol)) <sup>[19]</sup> |
|-----------------|---|

End point description:

Serum samples were collected to evaluate renal specific biomarkers: urine beta-2 microglobulin/

creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                     | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|--------------------------------------|-----------------|----------------------|--|--|
| Subject group type                   | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed          | 88              | 182                  |  |  |
| Units: grams per mole (g/mol)        |                 |                      |  |  |
| arithmetic mean (standard deviation) |                 |                      |  |  |
| Baseline (Day 1)                     | 0.0 (± 0.04)    | 0.0 (± 0.03)         |  |  |
| Month 6/5                            | 0.0 (± 0.19)    | 0.0 (± 0.03)         |  |  |
| Month 12/11                          | 0.0 (± 0.04)    | 0.0 (± 0.02)         |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in percentage of participants with metabolic syndrome at month 12/11

|                 |   |
|-----------------|---|
| End point title | Change From Baseline in percentage of participants with metabolic syndrome at month 12/11 <sup>[20]</sup> |
|-----------------|---|

End point description:

Metabolic syndrome defined as cluster of conditions that occurred together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions included increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and at Month 12/11

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| <b>End point values</b>                  | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|--|-----------------|----------------------|--|--|
| Subject group type                       | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed              | 227             | 454                  |  |  |
| Units: Percentage of participants        |                 |                      |  |  |
| Yes (Baseline) to Yes (Month 12/11)      | 9               | 9                    |  |  |
| Yes (Baseline) to No (Month 12/11)       | 7               | 5                    |  |  |
| Yes (Baseline) to Missing (Month 12/11)  | 1               | 2                    |  |  |
| No (Baseline) to Yes (Month 12/11)       | 8               | 6                    |  |  |
| No (Baseline) to No (Month 12/11)        | 70              | 69                   |  |  |
| No (Baseline) to Missing ((Month 12/11)) | 6               | 8                    |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in percentage of participants with metabolic syndrome at month 6/5

|                 |   |
|-----------------|---|
| End point title | Change From Baseline in percentage of participants with metabolic syndrome at month 6/5 <sup>[21]</sup> |
|-----------------|---|

End point description:

Metabolic syndrome defined as cluster of conditions that occurred together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions included increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and at month 6/5

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| <b>End point values</b>               | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|---------------------------------------|-----------------|----------------------|--|--|
| Subject group type                    | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed           | 227             | 454                  |  |  |
| Units: Percentage of participants     |                 |                      |  |  |
| Yes (Baseline) to Yes (Month 6/5)     | 11              | 9                    |  |  |
| Yes (Baseline) to No (Month 6/5)      | 6               | 7                    |  |  |
| Yes (Baseline) to Missing (Month 6/5) | 0               | 1                    |  |  |
| No (Baseline) to Yes (Month 6/5)      | 10              | 5                    |  |  |
| No (Baseline) to No (Month 6/5)       | 71              | 74                   |  |  |
| No (Baseline) to Missing (Month 6/5)  | 2               | 5                    |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in homeostasis model of assessment-insulin resistance (HOMA-IR)

|                 |  |
|-----------------|--|
| End point title | Change from baseline in homeostasis model of assessment-insulin resistance (HOMA-IR) <sup>[22]</sup> |
|-----------------|--|

End point description:

The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance. HOMA-IR is calculated as fasting insulin microunits per liter (microU/L) multiplied by fasting glucose (nmol/L) divided by 22.5. Higher HOMA-IR values indicate increased insulin resistance; values <2 is generally regarded as normal. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                     | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|--------------------------------------|-----------------|----------------------|--|--|
| Subject group type                   | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed          | 210             | 409                  |  |  |
| Units: HOMA-IR score                 |                 |                      |  |  |
| arithmetic mean (standard deviation) |                 |                      |  |  |
| Baseline (Day 1)                     | 3.1 (± 5.06)    | 2.8 (± 4.05)         |  |  |
| Month 6/5                            | -0.1 (± 5.09)   | 0.3 (± 4.11)         |  |  |
| Month 12/11                          | -0.4 (± 3.76)   | 0.2 (± 3.99)         |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants with treatment preference as assessed using preference questionnaire at month 12/11 - Q2M

|                 |  |
|-----------------|--|
| End point title | Percentage of participants with treatment preference as assessed using preference questionnaire at month 12/11 - Q2M <sup>[23]</sup> |
|-----------------|--|

End point description:

Participants who had switched from the daily oral BIK regimen to CAB + RPV, were assessed as per the preference questionnaire every two months. There were 3 preference questions included to assess the preferred treatment 1) Long-acting injectable HIV medication, 2) Daily oral HIV medication, 3) No Preference. This endpoint was only planned to be analyzed for Q2M arm only. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. Data represented included maintenance withdrawal or Month 12/11.

End point type Secondary

End point timeframe:

Up to month 12/11

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                      | Oral lead-in phase (OLI) | Direct to injections (D2I) |  |  |
|---------------------------------------|--------------------------|----------------------------|--|--|
| Subject group type                    | Reporting group          | Reporting group            |  |  |
| Number of subjects analysed           | 163                      | 262                        |  |  |
| Units: Percentage of participants     |                          |                            |  |  |
| Long-acting injectable HIV medication | 87                       | 92                         |  |  |
| Daily oral HIV medication             | 7                        | 4                          |  |  |
| No Preference                         | 6                        | 5                          |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline in total treatment satisfaction score using HIV treatment satisfaction status questionnaire (HIVTSQs)

End point title Change from baseline in total treatment satisfaction score using HIV treatment satisfaction status questionnaire (HIVTSQs)<sup>[24]</sup>

End point description:

The HIVTSQs total treatment satisfaction score comprised of 11 items based on HIVTSQ questionnaire each graded on a scale of 0 (very dissatisfied) to 6 (very satisfied) which were summed to produce a total score range of 0-66. Higher scores represent greater treatment satisfaction. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

End point type Secondary

End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                     | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|--------------------------------------|-----------------|----------------------|--|--|
| Subject group type                   | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed          | 222             | 446                  |  |  |
| Units: Scores on scale               |                 |                      |  |  |
| arithmetic mean (standard deviation) |                 |                      |  |  |
| Baseline (Day 1)                     | 58.38 (± 8.229) | 57.88 (± 7.906)      |  |  |
| Month 6/5                            | -0.66 (± 7.417) | 3.99 (± 9.670)       |  |  |
| Month 12/11                          | -1.93 (± 8.045) | 4.21 (± 9.273)       |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in individual item scores using HIVTSQs

|                 |  |
|-----------------|--|
| End point title | Change from baseline in individual item scores using |
|-----------------|--|

End point description:

The individual item scores on HIVTSQs scale were rated on a scale of 6 (very satisfied, convenient, flexible, etc.) to -6 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and up to Month 12

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                              | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|---|-----------------|----------------------|--|--|
| Subject group type                            | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed                   | 222             | 446                  |  |  |
| Units: Scores on scale                        |                 |                      |  |  |
| arithmetic mean (standard deviation)          |                 |                      |  |  |
| I1=Satisfaction with current treatment,Day 1  | 5.6 (± 0.75)    | 5.5 (± 0.86)         |  |  |
| I1=Satisfaction with current treatment,M6/5   | -0.2 (± 0.91)   | 0.1 (± 1.10)         |  |  |
| I1=Satisfaction with current treatment,M12/11 | -0.3 (± 1.00)   | 0.2 (± 1.07)         |  |  |
| I2=Controlled HIV, Day 1                      | 5.8 (± 0.45)    | 5.8 (± 0.54)         |  |  |
| I2=Controlled HIV, M6/5                       | -0.1 (± 0.55)   | 0.0 (± 0.80)         |  |  |
| I2=Controlled HIV, M12/11                     | -0.1 (± 0.69)   | 0.0 (± 0.70)         |  |  |

|  |               |               |  |  |
|--|---------------|---------------|--|--|
| I3=Satisfaction with side effects, Day 1           | 5.5 (± 1.02)  | 5.5 (± 0.91)  |  |  |
| I3=Satisfaction with side effects,M6/5             | 0.0 (± 1.21)  | -0.3 (± 1.42) |  |  |
| I3=Satisfaction with side effects,M12/11           | 0.0 (± 1.16)  | -0.1 (± 1.38) |  |  |
| I4=Satisfaction with treatment demands, Day 1      | 5.2 (± 1.21)  | 5.2 (± 1.16)  |  |  |
| I4=Satisfaction with treatment demands,M6/5        | -0.1 (± 1.28) | 0.4 (± 1.32)  |  |  |
| I4=Satisfaction with treatment demands,M12/11      | -0.2 (± 1.35) | 0.3 (± 1.33)  |  |  |
| I5=Treatment convenience, Day 1                    | 5.2 (± 1.16)  | 5.0 (± 1.24)  |  |  |
| I5=Treatment convenience, M6/5                     | -0.1 (± 1.30) | 0.6 (± 1.42)  |  |  |
| I5=Treatment convenience, M12/11                   | -0.2 (± 1.33) | 0.7 (± 1.43)  |  |  |
| I6=Treatment flexibility, Day 1                    | 4.9 (± 1.55)  | 4.7 (± 1.70)  |  |  |
| I6=Treatment flexibility,M6/5                      | 0.0 (± 1.58)  | 0.9 (± 1.77)  |  |  |
| I6=Treatment flexibility, M12/11                   | -0.1 (± 1.58) | 0.9 (± 1.74)  |  |  |
| I7=Satisfaction with understanding of HIV, Day 1   | 5.5 (± 0.92)  | 5.5 (± 0.80)  |  |  |
| I7=Satisfaction with understanding of HIV,M6/5     | 0.1 (± 0.75)  | 0.2 (± 0.81)  |  |  |
| I7=Satisfaction with understanding of HIV,M12/11   | 0.1 (± 0.78)  | 0.1 (± 0.86)  |  |  |
| I8=Treatment fitting in with lifestyle, Day 1      | 5.1 (± 1.11)  | 5.0 (± 1.20)  |  |  |
| I8=Treatment fitting in with lifestyle, M6/5       | -0.1 (± 1.26) | 0.7 (± 1.36)  |  |  |
| I8=Treatment fitting in with lifestyle, M12/11     | -0.2 (± 1.38) | 0.7 (± 1.31)  |  |  |
| I9=Recommendation of treatment for HIV,Day 1       | 5.5 (± 1.02)  | 5.5 (± 0.86)  |  |  |
| I9=Recommendation of treatment for HIV,M6/5        | 0.0 (± 1.09)  | 0.2 (± 1.10)  |  |  |
| I9=Recommendation of treatment for HIV,M12/11      | -0.1 (± 1.04) | 0.2 (± 1.04)  |  |  |
| I10=Satisfaction with treatment continuation,Day 1 | 4.9 (± 1.28)  | 4.9 (± 1.23)  |  |  |
| I10=Satisfaction with treatment continuation,M6/5  | 0.0 (± 1.38)  | 0.8 (± 1.54)  |  |  |
| I10=Satisfaction with treatm. continuation,M12/11  | -0.2 (± 1.45) | 0.9 (± 1.49)  |  |  |
| I11=Ease/difficulty with current treatment,Day 1   | 5.3 (± 1.06)  | 5.2 (± 1.10)  |  |  |
| I11=Ease/difficulty with current treatment,M 6/5   | -0.2 (± 1.20) | 0.5 (± 1.34)  |  |  |
| I11=Ease/difficulty with current treatment,M12/11  | -0.3 (± 1.13) | 0.5 (± 1.34)  |  |  |
| I12=Satisfaction with treatm. discomfort,Day 1     | 5.6 (± 0.94)  | 5.5 (± 1.02)  |  |  |
| I12=Satisfaction with treatm. discomfort,M6/5      | -0.1 (± 0.93) | -0.6 (± 1.64) |  |  |
| I12=Satisfaction with treatm. discomfort,M12/11    | -0.2 (± 1.09) | -0.5 (± 1.54) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: HIV treatment satisfaction change questionnaire (HIVTSQc) total score at Month 12/11

|                 |  |
|-----------------|--|
| End point title | HIV treatment satisfaction change questionnaire (HIVTSQc) total score at Month 12/11 <sup>[26]</sup> |
|-----------------|--|

### End point description:

HIV treatment satisfaction change questionnaire (HIVTSQc) total Score is computed with items 1-11 which were summed to produce a total score range of -33 to 33. Higher score indicated greater improvement in the satisfaction with the treatment and lower score indicated greater deterioration in treatment satisfaction. A score of 0 represents no change. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

### End point timeframe:

At Month 12/11

### Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                     | Biktarvy (BIK)   | Q2M (OLI + D2I)      |  |  |
|--------------------------------------|------------------|----------------------|--|--|
| Subject group type                   | Reporting group  | Subject analysis set |  |  |
| Number of subjects analysed          | 214              | 426                  |  |  |
| Units: Scores on scale               |                  |                      |  |  |
| arithmetic mean (standard deviation) | 16.89 (± 14.299) | 26.97 (± 10.135)     |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Individual item scores of HIVTSQc at Month 12/11

|                 |  |
|-----------------|--|
| End point title | Individual item scores of HIVTSQc at Month 12/11 <sup>[27]</sup> |
|-----------------|--|

### End point description:

Individual item scores were rated on a scale of +3 (much more satisfied', 'much more convenient', 'much more flexible') to -3 (much less satisfied', 'much less convenient', 'much less flexible'). Higher score indicates greater improvement, and lower score indicates greater deterioration in satisfaction with each aspect of treatment. A score of 0 represents no change. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

### End point timeframe:

At Month 12/11

### Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| End point values                               | Biktarvy (BIK)  | Q2M (OLI + D2I)      |  |  |
|--|-----------------|----------------------|--|--|
| Subject group type                             | Reporting group | Subject analysis set |  |  |
| Number of subjects analysed                    | 214             | 427                  |  |  |
| Units: Scores on scale                         |                 |                      |  |  |
| arithmetic mean (standard deviation)           |                 |                      |  |  |
| I1=Satisfaction with current treatment         | 1.60 (± 1.417)  | 2.56 (± 1.043)       |  |  |
| I 2=Controlled HIV                             | 1.88 (± 1.375)  | 2.47 (± 1.086)       |  |  |
| I3=Satisfaction with side effects              | 1.63 (± 1.463)  | 2.10 (± 1.388)       |  |  |
| I4=Satisfaction with treatment demands         | 1.42 (± 1.560)  | 2.41 (± 1.109)       |  |  |
| I5=Treatment convenience                       | 1.38 (± 1.520)  | 2.50 (± 1.070)       |  |  |
| I6=Treatment flexibility                       | 1.24 (± 1.591)  | 2.41 (± 1.138)       |  |  |
| I7=Satisfaction with understanding of HIV      | 1.94 (± 1.297)  | 2.35 (± 1.065)       |  |  |
| I8=Treatment fitting in with lifestyle         | 1.43 (± 1.489)  | 2.56 (± 0.994)       |  |  |
| I9=Recommendation of current treatment for HIV | 1.73 (± 1.467)  | 2.61 (± 1.065)       |  |  |
| I10=Satisfaction with treatment continuation   | 1.22 (± 1.602)  | 2.58 (± 1.093)       |  |  |
| I11=Ease/difficulty with treatment             | 1.43 (± 1.542)  | 2.46 (± 1.107)       |  |  |
| I12=Satisfaction with discomfort of treatment  | 1.64 (± 1.465)  | 1.85 (± 1.530)       |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from month 2/1 in dimension scores using perception of injection (PIN) questionnaire - Q2M

|                 |   |
|-----------------|---|
| End point title | Change from month 2/1 in dimension scores using perception of injection (PIN) questionnaire - Q2M <sup>[28]</sup> |
|-----------------|---|

End point description:

The PIN questionnaire was used to explore the dimension scores based on 4 dimensions including acceptance of injection site reactions (ISRs), Bother from ISRs, Leg movement and Sleep categories. Domain scores were calculated as a mean of all items with the domain. The PIN response options range from 1 (totally acceptable) to 5 (not at all acceptable). This endpoint was only planned to be analyzed for Q2M arm. Month 2/1 refers to the Month 2 (OLI and BIK) visit/Month 1 (DTI) visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Month 2/1 up to Month 12

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| <b>End point values</b>              | Oral lead-in phase (OLI) | Direct to injections (D2I) |  |  |
|--------------------------------------|--------------------------|----------------------------|--|--|
| Subject group type                   | Reporting group          | Reporting group            |  |  |
| Number of subjects analysed          | 163                      | 271                        |  |  |
| Units: Scores on scale               |                          |                            |  |  |
| arithmetic mean (standard deviation) |                          |                            |  |  |
| Bother of ISRs, Month 2/1            | 1.58 (± 0.568)           | 1.60 (± 0.583)             |  |  |
| Bother of ISRs, Month 6/5            | 0.01 (± 0.528)           | -0.03 (± 0.590)            |  |  |
| Bother of ISRs, Month 12/11          | 0.08 (± 0.594)           | -0.04 (± 0.583)            |  |  |
| Leg Movement, Month 2/1              | 1.93 (± 1.013)           | 1.83 (± 0.913)             |  |  |
| Leg Movement, Month 6/5              | -0.14 (± 0.779)          | -0.22 (± 0.868)            |  |  |
| Leg Movement, Month 12/11            | -0.18 (± 0.859)          | -0.24 (± 0.817)            |  |  |
| Sleep, Month 2/1                     | 1.83 (± 0.936)           | 1.87 (± 0.965)             |  |  |
| Sleep, Month 6/5                     | -0.01 (± 0.915)          | -0.16 (± 0.869)            |  |  |
| Sleep, Month 12/11                   | -0.07 (± 0.948)          | -0.17 (± 0.870)            |  |  |
| Acceptance, Month 2/1                | 2.02 (± 1.017)           | 2.05 (± 0.949)             |  |  |
| Acceptance, Month 6/5                | -0.14 (± 0.906)          | -0.13 (± 0.879)            |  |  |
| Acceptance, Month 12/11              | -0.20 (± 0.873)          | -0.26 (± 0.856)            |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from month 2/1 in individual item scores using PIN questionnaire- Q2M

|                 |  |
|-----------------|--|
| End point title | Change from month 2/1 in individual item scores using PIN questionnaire- Q2M <sup>[29]</sup> |
|-----------------|--|

End point description:

The PIN questionnaire was used to explore the individual item scores based on anxiety before, pain, satisfaction, anxiety after and willingness categories. The items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is very dissatisfied and 5 was very satisfied. This endpoint was only planned to be analyzed for Q2M arm. Month 2/1 refers to the Month 2 (OLI and BIK) visit/Month 1 (DTI) visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Month 2/1 up to Month 12

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per study design, the endpoints were presented for OLI + D2I arms combined as Q2M. Whereas, the baseline period was separated as OLI and D2I.

| <b>End point values</b>              | Oral lead-in phase (OLI) | Direct to injections (D2I) |  |  |
|--------------------------------------|--------------------------|----------------------------|--|--|
| Subject group type                   | Reporting group          | Reporting group            |  |  |
| Number of subjects analysed          | 163                      | 271                        |  |  |
| Units: Scores on scale               |                          |                            |  |  |
| arithmetic mean (standard deviation) |                          |                            |  |  |
| Anxiety Before, Month 2/1            | 1.9 (± 1.02)             | 1.9 (± 1.02)               |  |  |
| Anxiety Before, Month 6/5            | -0.14 (± 1.021)          | -0.22 (± 1.000)            |  |  |
| Anxiety Before, Month 12/11          | -0.28 (± 0.973)          | -0.22 (± 0.914)            |  |  |
| Pain, Month 2/1                      | 1.8 (± 0.88)             | 2.0 (± 0.93)               |  |  |
| Pain, Month 6/5                      | 0.09 (± 0.907)           | -0.03 (± 0.935)            |  |  |
| Pain, Month 12/11                    | 0.13 (± 0.995)           | 0.02 (± 0.943)             |  |  |
| Satisfaction, Month 2/1              | 1.7 (± 0.90)             | 1.6 (± 0.81)               |  |  |
| Satisfaction, Month 6/5              | -0.06 (± 0.837)          | 0.00 (± 0.867)             |  |  |
| Satisfaction, Month 12/11            | -0.12 (± 0.861)          | -0.11 (± 0.830)            |  |  |
| Anxiety After, Month 2/1             | 1.8 (± 1.12)             | 1.7 (± 0.96)               |  |  |
| Anxiety After, Month 6/5             | -0.14 (± 0.994)          | -0.04 (± 0.916)            |  |  |
| Anxiety After, Month 12/11           | -0.24 (± 0.947)          | -0.16 (± 0.850)            |  |  |
| Willingness, Month 2/1               | 1.4 (± 0.76)             | 1.4 (± 0.78)               |  |  |
| Willingness, Month 6/5               | 0.01 (± 0.716)           | -0.08 (± 0.794)            |  |  |
| Willingness, Month 12/11             | -0.01 (± 0.744)          | -0.10 (± 0.742)            |  |  |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to end of Extension Phase (approximately Month 27).

Adverse event reporting additional description:

AEs are reported based on Safety set population, which included all randomized participants who received at least one dose of study drug, based on the study phase they were included in. The Safety set included all participants irrespective of eligibility criteria violation and GCP non-compliance, since they received at least a study intervention d

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 24.1 |
|--------------------|------|

### Reporting groups

|                       |                          |
|-----------------------|--------------------------|
| Reporting group title | Oral lead-in phase (OLI) |
|-----------------------|--------------------------|

Reporting group description:

Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM), and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections once every 2 months (Q2M) until Month 12 (Maintenance Phase). The participants had the option to continue the regimen in the Extension Phase.

|                       |                  |
|-----------------------|------------------|
| Reporting group title | Switch Q2M Group |
|-----------------------|------------------|

Reporting group description:

Eligible participants with HIV-1 who received BIK tablet orally switched treatment after month 12 (Extension Phase) to CAB LA 600 mg + RPV LA 900 mg regimen, administered once every 2 months.

|                       |                |
|-----------------------|----------------|
| Reporting group title | Biktarvy (BIK) |
|-----------------------|----------------|

Reporting group description:

Participants with HIV-1 received BIK tablet orally until month 12. BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF).

|                       |                            |
|-----------------------|----------------------------|
| Reporting group title | Direct to injections (D2I) |
|-----------------------|----------------------------|

Reporting group description:

Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until Month 11. The participants had the option to continue the regimen in the Extension Phase.

| <b>Serious adverse events</b>                                       | Oral lead-in phase (OLI) | Switch Q2M Group | Biktarvy (BIK)   |
|---|--------------------------|------------------|------------------|
| Total subjects affected by serious adverse events                   |                          |                  |                  |
| subjects affected / exposed   | 11 / 175 (6.29%)         | 5 / 145 (3.45%)  | 15 / 227 (6.61%) |
| number of deaths (all causes)                                       | 0                        | 1                | 1                |
| number of deaths resulting from adverse events                      | 0                        | 0                | 0                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                          |                  |                  |
| Glioblastoma multiforme   |                          |                  |                  |
| alternative dictionary used: v24.1<br>24.1                          |                          |                  |                  |

|  |                 |                 |                 |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed  | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all                                | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                                     | 0 / 0           | 0 / 0           | 0 / 0           |
| Bladder transitional cell carcinoma<br>alternative dictionary used: v24.1 24.1 |                 |                 |                 |
| subjects affected / exposed  | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all                                | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                                     | 0 / 0           | 0 / 0           | 0 / 0           |
| Surgical and medical procedures  |                 |                 |                 |
| Abortion induced<br>alternative dictionary used: v24.1 24.1                    |                 |                 |                 |
| subjects affected / exposed  | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all                                | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                                     | 0 / 0           | 0 / 0           | 0 / 0           |
| General disorders and administration site conditions                           |                 |                 |                 |
| Pyrexia<br>alternative dictionary used: v24.1 24.1                             |                 |                 |                 |
| subjects affected / exposed  | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all                                | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all                                     | 0 / 0           | 0 / 0           | 0 / 0           |
| Injection site pain<br>alternative dictionary used: v24.1 24.1                 |                 |                 |                 |
| subjects affected / exposed  | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all                                | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                                     | 0 / 0           | 0 / 0           | 0 / 0           |
| Sudden death   |                 |                 |                 |
| subjects affected / exposed  | 0 / 175 (0.00%) | 1 / 145 (0.69%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all                                | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all                                     | 0 / 0           | 0 / 1           | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders                                |                 |                 |                 |
| Pulmonary embolism<br>alternative dictionary used: v24.1 24.1                  |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                           | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all       | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Psychiatric disorders</b>                          |                 |                 |                 |
| Drug abuse  |                 |                 |                 |
| alternative dictionary used: v24.1 24.1               |                 |                 |                 |
| subjects affected / exposed                           | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all       | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| Substance abuse                                       |                 |                 |                 |
| alternative dictionary used: v24.1 24.1               |                 |                 |                 |
| subjects affected / exposed                           | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all       | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Product issues</b>                                 |                 |                 |                 |
| Device breakage                                       |                 |                 |                 |
| alternative dictionary used: v24.1 24.1               |                 |                 |                 |
| subjects affected / exposed                           | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all       | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Investigations</b>                                 |                 |                 |                 |
| Alanine aminotransferase increased                    |                 |                 |                 |
| alternative dictionary used: v24.1 24.1               |                 |                 |                 |
| subjects affected / exposed                           | 2 / 175 (1.14%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all       | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| Blood creatine phosphokinase increased                |                 |                 |                 |
| alternative dictionary used: v24.1 24.1               |                 |                 |                 |
| subjects affected / exposed                           | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all       | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Injury, poisoning and procedural complications</b> |                 |                 |                 |
| Abdominal injury                                      |                 |                 |                 |

|  |                 |                 |                 |
|--|-----------------|-----------------|-----------------|
| alternative dictionary used: v24.1<br>24.1         |                 |                 |                 |
| subjects affected / exposed                        | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to<br>treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to<br>treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Overdose   |                 |                 |                 |
| alternative dictionary used: v24.1<br>24.1         |                 |                 |                 |
| subjects affected / exposed                        | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to<br>treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to<br>treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin laceration                                    |                 |                 |                 |
| alternative dictionary used: v24.1<br>24.1         |                 |                 |                 |
| subjects affected / exposed                        | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to<br>treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to<br>treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ulna fracture                                      |                 |                 |                 |
| alternative dictionary used: v24.1<br>24.1         |                 |                 |                 |
| subjects affected / exposed                        | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to<br>treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to<br>treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Radius fracture                                    |                 |                 |                 |
| alternative dictionary used: v24.1<br>24.1         |                 |                 |                 |
| subjects affected / exposed                        | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to<br>treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to<br>treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Joint dislocation                                  |                 |                 |                 |
| alternative dictionary used: v24.1<br>24.1         |                 |                 |                 |
| subjects affected / exposed                        | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to<br>treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to<br>treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Contusion  |                 |                 |                 |
| alternative dictionary used: v24.1<br>24.1         |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed   | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all                               | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all                                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Road traffic accident<br>alternative dictionary used: v24.1 24.1              |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 2 / 227 (0.88%) |
| occurrences causally related to treatment / all                               | 0 / 0           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all                                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin abrasion<br>alternative dictionary used: v24.1 24.1                      |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all                               | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders   |                 |                 |                 |
| Atrial fibrillation<br>alternative dictionary used: v24.1 24.1                |                 |                 |                 |
| subjects affected / exposed   | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all                               | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Acute myocardial infarction<br>alternative dictionary used: v24.1 24.1        |                 |                 |                 |
| subjects affected / exposed   | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all                               | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                                    | 0 / 0           | 0 / 0           | 0 / 1           |
| Nervous system disorders  |                 |                 |                 |
| Haemorrhagic transformation stroke<br>alternative dictionary used: v24.1 24.1 |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all                               | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Encephalopathy<br>alternative dictionary used: v24.1 24.1                     |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed   | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all   | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all  | 0 / 0           | 0 / 0           | 0 / 1           |
| Brain injury<br>alternative dictionary used: v24.1 24.1   |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all   | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all  | 0 / 0           | 0 / 0           | 0 / 0           |
| Syncope<br>alternative dictionary used: v24.1 24.1  |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all   | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all  | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders<br>Anorectal disorder<br>alternative dictionary used: v24.1 24.1     |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all   | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all  | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders<br>Cholecystitis<br>alternative dictionary used: v24.1 24.1             |                 |                 |                 |
| subjects affected / exposed   | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all   | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all  | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatitis acute   |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 1 / 145 (0.69%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all   | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all  | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin and subcutaneous tissue disorders<br>Angioedema<br>alternative dictionary used: v24.1 24.1 |                 |                 |                 |

|  |                 |                 |                 |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed                            | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Renal and urinary disorders</b>                     |                 |                 |                 |
| Urinary retention                                      |                 |                 |                 |
| alternative dictionary used: v24.1 24.1                |                 |                 |                 |
| subjects affected / exposed                            | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0           | 0 / 0           |
| Acute kidney injury                                    |                 |                 |                 |
| alternative dictionary used: v24.1 24.1                |                 |                 |                 |
| subjects affected / exposed                            | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all        | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Musculoskeletal and connective tissue disorders</b> |                 |                 |                 |
| Bursitis   |                 |                 |                 |
| alternative dictionary used: v24.1 24.1                |                 |                 |                 |
| subjects affected / exposed                            | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all        | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0           | 0 / 0           |
| Back pain  |                 |                 |                 |
| alternative dictionary used: v24.1 24.1                |                 |                 |                 |
| subjects affected / exposed                            | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0           | 0 / 0           |
| Intervertebral disc protrusion                         |                 |                 |                 |
| alternative dictionary used: v24.1 24.1                |                 |                 |                 |
| subjects affected / exposed                            | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all        | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Infections and infestations</b>                     |                 |                 |                 |
| COVID-19   |                 |                 |                 |
| alternative dictionary used: v24.1 24.1                |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cellulitis                                      |                 |                 |                 |
| alternative dictionary used: v24.1 24.1         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Anal abscess                                    |                 |                 |                 |
| alternative dictionary used: v24.1 24.1         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Respiratory tract infection                     |                 |                 |                 |
| alternative dictionary used: v24.1 24.1         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Tonsillitis                                     |                 |                 |                 |
| alternative dictionary used: v24.1 24.1         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis                                  |                 |                 |                 |
| alternative dictionary used: v24.1 24.1         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 175 (0.00%) | 1 / 145 (0.69%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Herpes simplex meningoencephalitis              |                 |                 |                 |
| alternative dictionary used: v24.1 24.1         |                 |                 |                 |
| subjects affected / exposed                     | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Herpes simplex meningitis<br>alternative dictionary used: v24.1<br>24.1                     |                 |                 |                 |
| subjects affected / exposed   | 1 / 175 (0.57%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to<br>treatment / all  | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to<br>treatment / all   | 0 / 0           | 0 / 0           | 0 / 0           |
| COVID-19 pneumonia<br>alternative dictionary used: v24.1<br>24.1                            |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences causally related to<br>treatment / all  | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to<br>treatment / all   | 0 / 0           | 0 / 0           | 0 / 0           |
| Appendicitis<br>alternative dictionary used: v24.1<br>24.1                                  |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 1 / 145 (0.69%) | 1 / 227 (0.44%) |
| occurrences causally related to<br>treatment / all  | 0 / 0           | 0 / 1           | 0 / 1           |
| deaths causally related to<br>treatment / all   | 0 / 0           | 0 / 0           | 0 / 0           |
| Tuberculosis<br>alternative dictionary used: v24.1<br>24.1                                  |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to<br>treatment / all  | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to<br>treatment / all   | 0 / 0           | 0 / 0           | 0 / 0           |
| Cytomegalovirus infection   |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 1 / 145 (0.69%) | 0 / 227 (0.00%) |
| occurrences causally related to<br>treatment / all  | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to<br>treatment / all   | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatitis C   |                 |                 |                 |
| subjects affected / exposed   | 0 / 175 (0.00%) | 1 / 145 (0.69%) | 0 / 227 (0.00%) |
| occurrences causally related to<br>treatment / all  | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to<br>treatment / all   | 0 / 0           | 0 / 0           | 0 / 0           |
| Metabolism and nutrition disorders<br>Obesity<br>alternative dictionary used: v24.1<br>24.1 |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 175 (0.00%) | 0 / 145 (0.00%) | 1 / 227 (0.44%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

| <b>Serious adverse events</b>                                       | Direct to injections (D2I) |  |  |
|---|----------------------------|--|--|
| Total subjects affected by serious adverse events                   |                            |  |  |
| subjects affected / exposed   | 10 / 279 (3.58%)           |  |  |
| number of deaths (all causes)                                       | 0                          |  |  |
| number of deaths resulting from adverse events                      | 0                          |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                            |  |  |
| Glioblastoma multiforme   |                            |  |  |
| alternative dictionary used: v24.1 24.1                             |                            |  |  |
| subjects affected / exposed   | 1 / 279 (0.36%)            |  |  |
| occurrences causally related to treatment / all                     | 0 / 1                      |  |  |
| deaths causally related to treatment / all                          | 0 / 0                      |  |  |
| Bladder transitional cell carcinoma                                 |                            |  |  |
| alternative dictionary used: v24.1 24.1                             |                            |  |  |
| subjects affected / exposed   | 0 / 279 (0.00%)            |  |  |
| occurrences causally related to treatment / all                     | 0 / 0                      |  |  |
| deaths causally related to treatment / all                          | 0 / 0                      |  |  |
| Surgical and medical procedures                                     |                            |  |  |
| Abortion induced  |                            |  |  |
| alternative dictionary used: v24.1 24.1                             |                            |  |  |
| subjects affected / exposed   | 1 / 279 (0.36%)            |  |  |
| occurrences causally related to treatment / all                     | 0 / 1                      |  |  |
| deaths causally related to treatment / all                          | 0 / 0                      |  |  |
| General disorders and administration site conditions                |                            |  |  |
| Pyrexia   |                            |  |  |
| alternative dictionary used: v24.1 24.1                             |                            |  |  |
| subjects affected / exposed   | 0 / 279 (0.00%)            |  |  |
| occurrences causally related to treatment / all                     | 0 / 0                      |  |  |
| deaths causally related to treatment / all                          | 0 / 0                      |  |  |
| Injection site pain   |                            |  |  |
| alternative dictionary used: v24.1 24.1                             |                            |  |  |

|   |                 |  |  |
|---|-----------------|--|--|
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Sudden death                                    |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Respiratory, thoracic and mediastinal disorders |                 |  |  |
| Pulmonary embolism                              |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Psychiatric disorders                           |                 |  |  |
| Drug abuse                                      |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Substance abuse                                 |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Product issues                                  |                 |  |  |
| Device breakage                                 |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Investigations                                  |                 |  |  |
| Alanine aminotransferase increased              |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |

|   |                 |  |  |
|---|-----------------|--|--|
| subjects affected / exposed                     | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Blood creatine phosphokinase increased          |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Injury, poisoning and procedural complications  |                 |  |  |
| Abdominal injury                                |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Overdose  |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Skin laceration                                 |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Ulna fracture                                   |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Radius fracture                                 |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |

|   |                 |  |  |
|---|-----------------|--|--|
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Joint dislocation                               |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Contusion                                       |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Road traffic accident                           |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Skin abrasion                                   |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cardiac disorders                               |                 |  |  |
| Atrial fibrillation                             |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Acute myocardial infarction                     |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |

|   |                 |  |  |
|---|-----------------|--|--|
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| <b>Nervous system disorders</b>                 |                 |  |  |
| Haemorrhagic transformation stroke              |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| <b>Encephalopathy</b>                           |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| <b>Brain injury</b>                             |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| <b>Syncope</b>                                  |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| <b>Gastrointestinal disorders</b>               |                 |  |  |
| Anorectal disorder                              |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| <b>Hepatobiliary disorders</b>                  |                 |  |  |
| Cholecystitis                                   |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |

|   |                 |  |  |
|---|-----------------|--|--|
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Hepatitis acute                                 |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Skin and subcutaneous tissue disorders          |                 |  |  |
| Angioedema                                      |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Renal and urinary disorders                     |                 |  |  |
| Urinary retention                               |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Acute kidney injury                             |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Musculoskeletal and connective tissue disorders |                 |  |  |
| Bursitis  |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Back pain                                       |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |

|   |                 |  |  |
|---|-----------------|--|--|
| subjects affected / exposed   | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all                           | 0 / 0           |  |  |
| deaths causally related to treatment / all                                | 0 / 0           |  |  |
| Intervertebral disc protrusion<br>alternative dictionary used: v24.1 24.1 |                 |  |  |
| subjects affected / exposed   | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all                           | 0 / 0           |  |  |
| deaths causally related to treatment / all                                | 0 / 0           |  |  |
| Infections and infestations   |                 |  |  |
| COVID-19<br>alternative dictionary used: v24.1 24.1                       |                 |  |  |
| subjects affected / exposed   | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all                           | 0 / 1           |  |  |
| deaths causally related to treatment / all                                | 0 / 0           |  |  |
| Cellulitis<br>alternative dictionary used: v24.1 24.1                     |                 |  |  |
| subjects affected / exposed   | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all                           | 0 / 0           |  |  |
| deaths causally related to treatment / all                                | 0 / 0           |  |  |
| Anal abscess<br>alternative dictionary used: v24.1 24.1                   |                 |  |  |
| subjects affected / exposed   | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all                           | 0 / 1           |  |  |
| deaths causally related to treatment / all                                | 0 / 0           |  |  |
| Respiratory tract infection<br>alternative dictionary used: v24.1 24.1    |                 |  |  |
| subjects affected / exposed   | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all                           | 0 / 0           |  |  |
| deaths causally related to treatment / all                                | 0 / 0           |  |  |
| Tonsillitis<br>alternative dictionary used: v24.1 24.1                    |                 |  |  |

|   |                 |  |  |
|---|-----------------|--|--|
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Pyelonephritis                                  |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Herpes simplex meningoencephalitis              |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Herpes simplex meningitis                       |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| COVID-19 pneumonia                              |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 1 / 279 (0.36%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Appendicitis                                    |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Tuberculosis                                    |                 |  |  |
| alternative dictionary used: v24.1 24.1         |                 |  |  |
| subjects affected / exposed                     | 0 / 279 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |

|  |                 |  |  |
|--|-----------------|--|--|
| Cytomegalovirus infection<br>subjects affected / exposed   | 0 / 279 (0.00%) |  |  |
| occurrences causally related to<br>treatment / all   | 0 / 0           |  |  |
| deaths causally related to<br>treatment / all  | 0 / 0           |  |  |
| Hepatitis C<br>subjects affected / exposed   | 0 / 279 (0.00%) |  |  |
| occurrences causally related to<br>treatment / all   | 0 / 0           |  |  |
| deaths causally related to<br>treatment / all  | 0 / 0           |  |  |
| Metabolism and nutrition disorders<br>Obesity<br>alternative dictionary used: v24.1<br>24.1<br>subjects affected / exposed | 0 / 279 (0.00%) |  |  |
| occurrences causally related to<br>treatment / all   | 0 / 0           |  |  |
| deaths causally related to<br>treatment / all  | 0 / 0           |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>   | Oral lead-in phase<br>(OLI) | Switch Q2M Group  | Biktarvy (BIK)    |
|---|-----------------------------|-------------------|-------------------|
| Total subjects affected by non-serious<br>adverse events<br>subjects affected / exposed   | 156 / 175 (89.14%)          | 76 / 145 (52.41%) | 77 / 227 (33.92%) |
| Nervous system disorders<br>Headache<br>alternative dictionary used: v24.1<br>24.1<br>subjects affected / exposed   | 17 / 175 (9.71%)            | 0 / 145 (0.00%)   | 12 / 227 (5.29%)  |
| occurrences (all)   | 17                          | 0                 | 12                |
| General disorders and administration<br>site conditions<br>Injection site pain<br>alternative dictionary used: v24.1<br>24.1<br>subjects affected / exposed | 106 / 175 (60.57%)          | 55 / 145 (37.93%) | 1 / 227 (0.44%)   |
| occurrences (all)   | 106                         | 55                | 2                 |
| Injection site swelling<br>alternative dictionary used: v24.1<br>24.1<br>subjects affected / exposed  | 15 / 175 (8.57%)            | 0 / 145 (0.00%)   | 0 / 227 (0.00%)   |
| occurrences (all)   | 15                          | 0                 | 0                 |
| Injection site nodule   |                             |                   |                   |

|  |                   |                 |                 |
|--|-------------------|-----------------|-----------------|
| alternative dictionary used: v24.1<br>24.1             |                   |                 |                 |
| subjects affected / exposed                            | 17 / 175 (9.71%)  | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences (all)                                      | 17                | 0               | 0               |
| <b>Fatigue</b>   |                   |                 |                 |
| alternative dictionary used: v24.1<br>24.1             |                   |                 |                 |
| subjects affected / exposed                            | 17 / 175 (9.71%)  | 0 / 145 (0.00%) | 6 / 227 (2.64%) |
| occurrences (all)                                      | 17                | 0               | 7               |
| <b>Injection site discomfort</b>                       |                   |                 |                 |
| alternative dictionary used: v24.1<br>24.1             |                   |                 |                 |
| subjects affected / exposed                            | 17 / 175 (9.71%)  | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences (all)                                      | 17                | 0               | 0               |
| <b>Pyrexia</b>   |                   |                 |                 |
| alternative dictionary used: v24.1<br>24.1             |                   |                 |                 |
| subjects affected / exposed                            | 10 / 175 (5.71%)  | 0 / 145 (0.00%) | 8 / 227 (3.52%) |
| occurrences (all)                                      | 10                | 0               | 8               |
| <b>Injection site induration</b>                       |                   |                 |                 |
| alternative dictionary used: v24.1<br>24.1             |                   |                 |                 |
| subjects affected / exposed                            | 20 / 175 (11.43%) | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences (all)                                      | 20                | 0               | 0               |
| <b>Gastrointestinal disorders</b>                      |                   |                 |                 |
| <b>Diarrhoea</b>                                       |                   |                 |                 |
| alternative dictionary used: v24.1<br>24.1             |                   |                 |                 |
| subjects affected / exposed                            | 8 / 175 (4.57%)   | 0 / 145 (0.00%) | 9 / 227 (3.96%) |
| occurrences (all)                                      | 8                 | 0               | 9               |
| <b>Musculoskeletal and connective tissue disorders</b> |                   |                 |                 |
| <b>Arthralgia</b>                                      |                   |                 |                 |
| subjects affected / exposed                            | 8 / 175 (4.57%)   | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences (all)                                      | 8                 | 0               | 0               |
| <b>Back pain</b>                                       |                   |                 |                 |
| subjects affected / exposed                            | 10 / 175 (5.71%)  | 0 / 145 (0.00%) | 0 / 227 (0.00%) |
| occurrences (all)                                      | 10                | 0               | 0               |
| <b>Infections and infestations</b>                     |                   |                 |                 |
| <b>COVID-19</b>  |                   |                 |                 |
| alternative dictionary used: v24.1<br>24.1             |                   |                 |                 |

|  |                   |                   |                   |
|--|-------------------|-------------------|-------------------|
| subjects affected / exposed                | 34 / 175 (19.43%) | 21 / 145 (14.48%) | 38 / 227 (16.74%) |
| occurrences (all)                          | 34                | 21                | 38                |
| Nasopharyngitis                            |                   |                   |                   |
| alternative dictionary used: v24.1<br>24.1 |                   |                   |                   |
| subjects affected / exposed                | 8 / 175 (4.57%)   | 0 / 145 (0.00%)   | 10 / 227 (4.41%)  |
| occurrences (all)                          | 8                 | 0                 | 13                |
| Syphilis                                   |                   |                   |                   |
| alternative dictionary used: v24.1<br>24.1 |                   |                   |                   |
| subjects affected / exposed                | 8 / 175 (4.57%)   | 0 / 145 (0.00%)   | 9 / 227 (3.96%)   |
| occurrences (all)                          | 8                 | 0                 | 10                |

|  |                               |  |  |
|--|-------------------------------|--|--|
| <b>Non-serious adverse events</b>                        | Direct to injections<br>(D2I) |  |  |
| Total subjects affected by non-serious<br>adverse events |                               |  |  |
| subjects affected / exposed                              | 257 / 279 (92.11%)            |  |  |
| Nervous system disorders                                 |                               |  |  |
| Headache   |                               |  |  |
| alternative dictionary used: v24.1<br>24.1               |                               |  |  |
| subjects affected / exposed                              | 35 / 279 (12.54%)             |  |  |
| occurrences (all)  | 35                            |  |  |
| General disorders and administration<br>site conditions  |                               |  |  |
| Injection site pain                                      |                               |  |  |
| alternative dictionary used: v24.1<br>24.1               |                               |  |  |
| subjects affected / exposed                              | 182 / 279 (65.23%)            |  |  |
| occurrences (all)  | 182                           |  |  |
| Injection site swelling                                  |                               |  |  |
| alternative dictionary used: v24.1<br>24.1               |                               |  |  |
| subjects affected / exposed                              | 27 / 279 (9.68%)              |  |  |
| occurrences (all)  | 27                            |  |  |
| Injection site nodule                                    |                               |  |  |
| alternative dictionary used: v24.1<br>24.1               |                               |  |  |
| subjects affected / exposed                              | 26 / 279 (9.32%)              |  |  |
| occurrences (all)  | 26                            |  |  |
| Fatigue  |                               |  |  |
| alternative dictionary used: v24.1<br>24.1               |                               |  |  |

|   |  |  |  |
|---|--|--|--|
| <p>subjects affected / exposed<br/>occurrences (all)</p> <p>14 / 279 (5.02%)<br/>14</p> <p>Injection site discomfort<br/>alternative dictionary used: v24.1<br/>24.1<br/>subjects affected / exposed<br/>occurrences (all)</p> <p>26 / 279 (9.32%)<br/>26</p> <p>Pyrexia<br/>alternative dictionary used: v24.1<br/>24.1<br/>subjects affected / exposed<br/>occurrences (all)</p> <p>26 / 279 (9.32%)<br/>26</p> <p>Injection site induration<br/>alternative dictionary used: v24.1<br/>24.1<br/>subjects affected / exposed<br/>occurrences (all)</p> <p>17 / 279 (6.09%)<br/>17</p> |  |  |  |
| <p>Gastrointestinal disorders<br/>Diarrhoea<br/>alternative dictionary used: v24.1<br/>24.1<br/>subjects affected / exposed<br/>occurrences (all)</p> <p>21 / 279 (7.53%)<br/>21</p>  |  |  |  |
| <p>Musculoskeletal and connective tissue disorders<br/>Arthralgia<br/>subjects affected / exposed<br/>occurrences (all)</p> <p>16 / 279 (5.73%)<br/>16</p> <p>Back pain<br/>subjects affected / exposed<br/>occurrences (all)</p> <p>17 / 279 (6.09%)<br/>17</p>  |  |  |  |
| <p>Infections and infestations<br/>COVID-19<br/>alternative dictionary used: v24.1<br/>24.1<br/>subjects affected / exposed<br/>occurrences (all)</p> <p>50 / 279 (17.92%)<br/>50</p> <p>Nasopharyngitis<br/>alternative dictionary used: v24.1<br/>24.1<br/>subjects affected / exposed<br/>occurrences (all)</p> <p>25 / 279 (8.96%)<br/>25</p>   |  |  |  |

|  |                  |  |  |
|--|------------------|--|--|
| Syphilis                                   |                  |  |  |
| alternative dictionary used: v24.1<br>24.1 |                  |  |  |
| subjects affected / exposed                | 23 / 279 (8.24%) |  |  |
| occurrences (all)                          | 23               |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date              | Amendment  |
|-------------------|--|
| 30 June 2020      | The primary reason for protocol amendment 01 is to add minor clarifications to address study completion, PK collection, and endpoint timings. Country-specific details were added to Appendix 10 to address UK MHRA requirements. The protocol short title was updated. Corrections to typographical errors in protocol text and title were made throughout. |
| 08 September 2021 | The primary reason for protocol amendment 02 is to address and clarify comments raised during the course of the study and to implement country specific changes following regulatory review.   |
| 10 February 2022  | The primary reason for protocol amendment 03 is to address and clarify comments raised during the course of the study.   |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported